Fundraising FoxProtransitnanotherapy
1 known investors
Find your way into Protransitnanotherapy
Sign up to see every warm intro you have to Protransitnanotherapy
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Protransitnanotherapy team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ProTransit is developing Pro-MP, a patented sustained-release microparticle drug delivery platform that penetrates skin, scalp, eye, and mucosal tissues (and can be IV-administered) to deliver pharmaceutical active ingredients locally with minimal systemic uptake. Based on research from the University of Nebraska Medical Center, Creighton University, and USC Keck School of Medicine, the technology targets applications such as skin health and hair regrowth.
Investors · 1
Frequently asked questions
- What does Protransitnanotherapy do?
- ProTransit is developing Pro-MP, a patented sustained-release microparticle drug delivery platform that penetrates skin, scalp, eye, and mucosal tissues (and can be IV-administered) to deliver pharmaceutical active ingredients locally with minimal systemic uptake. Based on research from the University of Nebraska Medical Center, Creighton University, and USC Keck School of Medicine, the technology targets applications such as skin health and hair regrowth.
- Who are Protransitnanotherapy's investors?
- Protransitnanotherapy's investors include Invest Nebraska.